ArticlePharmaceutics2019

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.

Nina Hanke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.